29 / 31
100
80
60
40
20
0
0
2
4
6
8
10 12 14
Time (months)
Survival probability (%)
No bevacizumab prior anti-EGFR
Bevacizumab prior anti-EGFR
Median PFS: patients receiving bevacizumab as first-line
had a poorer PFS on anti-EGFR therapy compared to
chemotherapy alone (log-rank test P < 0.003):
-
Bevacizumab group 2.8 months (95% CI: 2-3 months)
- No-Bevacizumab group 4 months (95% CI: 3.3-5 months)
Using multivariate analysis, only previous treatment with
bevacizumab remained independently associated with a poorer
PFS:
–
HR (No bev prior anti-EGFR - Bev prior anti-EGFR)=
1.7 (95% CI: 1.06-2.3) p=0.03
Does Bevacizumab impact antiEGFR efficacy in
wtRAS
mCRC?